Equities Analysts Offer Predictions for CRL Q1 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – William Blair upped their Q1 2026 earnings per share estimates for shares of Charles River Laboratories International in a report released on Wednesday, May 7th. William Blair analyst M. Smock now expects that the medical research company will post earnings per share of $2.74 for the quarter, up from their previous estimate of $2.43. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q2 2026 earnings at $2.74 EPS and Q4 2026 earnings at $2.72 EPS.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.27 earnings per share.

CRL has been the subject of several other research reports. UBS Group reaffirmed a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. JPMorgan Chase & Co. cut their price target on Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their target price for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. Finally, Mizuho decreased their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $176.00.

Charles River Laboratories International Trading Down 1.8 %

NYSE:CRL opened at $138.84 on Friday. The company has a 50 day simple moving average of $138.40 and a two-hundred day simple moving average of $166.46. The company has a market cap of $6.82 billion, a PE ratio of 925.60, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $254.15.

Insider Activity

In related news, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James C. Foster bought 6,075 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several hedge funds have recently bought and sold shares of CRL. Deutsche Bank AG increased its holdings in shares of Charles River Laboratories International by 77.0% in the first quarter. Deutsche Bank AG now owns 411,419 shares of the medical research company’s stock worth $61,927,000 after purchasing an additional 178,927 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Charles River Laboratories International by 4.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 577,322 shares of the medical research company’s stock worth $86,899,000 after acquiring an additional 24,347 shares during the last quarter. ASR Vermogensbeheer N.V. purchased a new stake in shares of Charles River Laboratories International during the 1st quarter worth approximately $232,000. Exencial Wealth Advisors LLC bought a new position in shares of Charles River Laboratories International during the 1st quarter valued at approximately $393,000. Finally, J. Safra Sarasin Holding AG grew its holdings in shares of Charles River Laboratories International by 6.6% in the first quarter. J. Safra Sarasin Holding AG now owns 8,783 shares of the medical research company’s stock valued at $1,322,000 after purchasing an additional 540 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).